An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .
Completed
This study will be an open-label study to evaluate the effect of albiglutide on the pharmacokinetics and pharmacodynamics of a standard oral contraceptive regimen (Brevicon). The primary objective of this study is to demonstrate the lack of effect of albiglutide doses on the pharmacokinetics of norethindrone and ethinyl estradiol in healthy female subjects.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
06/13/2017
Locations: GSK Investigational Site, Austin, Texas
Conditions: Diabetes Mellitus, Type 2
A Drug Interaction Study of Albiglutide and Digoxin
Completed
This Phase I, open-label, sequential, single-center study evaluates the pharmacokinetics of digoxin when coadministered with albiglutide in healthy adult subjects.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/09/2017
Locations: GSK Investigational Site, Austin, Texas
Conditions: Diabetes Mellitus, Type 2
A Drug Interaction Study of Simvastatin and Albiglutide
Completed
This open-label study evaluates the pharmacokinetics of simvastatin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of simvastatin.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/07/2017
Locations: GSK Investigational Site, Austin, Texas
Conditions: Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
Completed
This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin. Subjects who are renally impaired with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately controlled on their current regimen of diet and exercise or their antidiabetic therapy of metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetic medications will be recruited into the study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2017
Locations: GSK Investigational Site, Arlington, Texas +31 locations
Conditions: Diabetes Mellitus, Type 2
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
Completed
This open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2017
Locations: GSK Investigational Site, Arlington, Texas +18 locations
Conditions: Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
Completed
This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/21/2016
Locations: GSK Investigational Site, Arlington, Texas +20 locations
Conditions: Diabetes Mellitus, Type 2
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
Completed
The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Arlington, Texas +40 locations
Conditions: Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
Completed
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Arlington, Texas +40 locations
Conditions: Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
Completed
The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Arlington, Texas +38 locations
Conditions: Diabetes Mellitus, Type 2
Pharmacokinetics/Pharmacodynamics of Albiglutide
Completed
The first part of the study includes a single dose treatment period to evaluate the pharmacokinetic bioequivalence of a subcutaneous injection of albiglutide from process 2 drug substance compared with process 3 drug substance. The second part of the treatment period will evaluate additional pharmacokinetic and pharmacodynamic parameters and safety and tolerability of repeat doses of albiglutide given weekly for 12 weeks from process 2 drug substance compared with process 3 drug substance. Subje... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Houston, Texas +5 locations
Conditions: Diabetes Mellitus, Type 2
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
Completed
The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Arlington, Texas +31 locations
Conditions: Diabetes Mellitus, Type 2
Safety and Efficacy of Albiglutide in Type 2 Diabetes
Completed
The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Arlington, Texas +38 locations
Conditions: Diabetes Mellitus, Type 2